With two concurrent FDA approvals, Incyte’s PD-1 inhibitor Zynyz has redeemed itself in anal cancer four years after an ...

Incyte INCY announced that the FDA has approved its new drug, Zynyz (retifanlimab-dlwr), a PD-1 inhibitor, for treating a new ...

Incyte Corp.’s Zynyz (retifanlimab-dlwr) has received another U.S. FDA approval and put some distance between it and a 2021 ...

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.

FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are ...

The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

FDA lifts hold on Scynexis' ibrexafungerp Phase 3 fungal infection trial, but GSK plans to end study. Incyte's Zynyz gets FDA ...

The FDA has approved Zynyz (retifanlimab-dlwr) to treat patients with squamous cell carcinoma of the anal canal.

PD-1 antibody was approved as first-line treatment for locally recurrent or metastatic squamous cell anal carcinoma.

The US Food and Drug Administration (FDA) has approved Incyte’s (Nasdaq: INCY) Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination ...